Proteomics and in silico approaches to extend understanding of the glutathione transferase superfamily of the tropical liver fluke Fasciola gigantica.
Article Details
- CitationCopy to clipboard
Morphew RM, Eccleston N, Wilkinson TJ, McGarry J, Perally S, Prescott M, Ward D, Williams D, Paterson S, Raman M, Ravikumar G, Khalid Saifullah M, Abbas Abidi SM, McVeigh P, Maule AG, Brophy PM, LaCourse EJ
Proteomics and in silico approaches to extend understanding of the glutathione transferase superfamily of the tropical liver fluke Fasciola gigantica.
J Proteome Res. 2012 Dec 7;11(12):5876-89. doi: 10.1021/pr300654w. Epub 2012 Nov 28.
- PubMed ID
- 23167294 [ View in PubMed]
- Abstract
Fasciolosis is an important foodborne, zoonotic disease of livestock and humans, with global annual health and economic losses estimated at several billion US$. Fasciola hepatica is the major species in temperate regions, while F. gigantica dominates in the tropics. In the absence of commercially available vaccines to control fasciolosis, increasing reports of resistance to current chemotherapeutic strategies and the spread of fasciolosis into new areas, new functional genomics approaches are being used to identify potential new drug targets and vaccine candidates. The glutathione transferase (GST) superfamily is both a candidate drug and vaccine target. This study reports the identification of a putatively novel Sigma class GST, present in a water-soluble cytosol extract from the tropical liver fluke F. gigantica. The GST was cloned and expressed as an enzymically active recombinant protein. This GST shares a greater identity with the human schistosomiasis GST vaccine currently at Phase II clinical trials than previously discovered F. gigantica GSTs, stimulating interest in its immuno-protective properties. In addition, in silico analysis of the GST superfamily of both F. gigantica and F. hepatica has revealed an additional Mu class GST, Omega class GSTs, and for the first time, a Zeta class member.